Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
isoflurane + atracurium
- Development stage
- Unknown
- Lead developer
- Ain Shams University
- Modality
- Small Molecules
- Administration
- Inhalation, Intravenous
01
Overview
isoflurane + atracurium is a combination of an inhalational general anesthetic and a non-depolarizing neuromuscular blocking agent (NMBA) used for balanced anesthesia. Isoflurane, a halogenated ether, induces and maintains general anesthesia by modulating various ion channels, including GABA-A and glycine receptors, and inhibiting NMDA receptors. Atracurium besylate is a competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, providing skeletal muscle relaxation required for surgical procedures. This specific combination was evaluated by Ain Shams University in a Phase 4 clinical trial to compare its effects on blood glucose levels in diabetic patients against total intravenous anesthesia (TIVA) during video-assisted thoracoscopy (VATS).
- Other names
- Isoflurane and Atracurium
02
Targets
GABRR (GABA-A receptor subunit rho)Mitochondrial ATP synthase and NADH dehydrogenaseGap junction alpha-8 proteinNicotinic Acetylcholine ReceptorNMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on isoflurane + atracurium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on isoflurane + atracurium.